Table 2. Patient characteristics in the immune checkpoint inhibitor group.
| Characteristics | Subtypes | TTF-1-negative (N=19) | TTF-1-positive (N=51) | P |
|---|---|---|---|---|
| Age, median [range], year | 76 [50–86] | 73 [43–85] | 0.61 | |
| Sex, n (%) | Male | 12 (63.2) | 35 (68.6) | 0.78 |
| Female | 7 (36.8) | 16 (31.4) | ||
| Smoking, n (%) | Ever | 14 (73.7) | 35 (68.6) | 0.78 |
| Never | 5 (26.3) | 16 (31.4) | ||
| PS, n (%) | 0–1 | 10 (52.6) | 38 (74.5) | 0.08 |
| ≥2 | 9 (47.4) | 13 (25.5) | ||
| Stage, n (%) | III | 1 (5.3) | 0 | 0.13 |
| IV | 14 (73.7) | 32 (62.7) | ||
| Recurrent | 4 (21.0) | 19 (37.3) | ||
| EGFR, n (%) | Positive | 0 | 9 (17.6) | 0.10 |
| Negative | 19 (100.0) | 42 (82.4) | ||
| ALK, n (%) | Positive | 1 (5.3) | 2 (3.9) | 1.00 |
| Negative | 18 (94.7) | 49 (96.1) | ||
| Pathology, n (%) | Adenocarcinoma | 14 (73.7) | 47 (92.2) | 0.05 |
| Other | 5 (26.3) | 4 (7.8) | ||
| PD-L1, n (%) | <1% | 6 (31.6) | 12 (23.5) | 0.17 |
| 1–49% | 8 (42.1) | 13 (25.5) | ||
| ≥50% | 5 (26.3) | 26 (51.0) | ||
| Regimen, n (%) | Pembrolizumab | 10 (52.6) | 32 (62.7) | 0.58 |
| Atezolizumab | 5 (26.3) | 8 (15.7) | ||
| Nivolumab | 4 (21.1) | 11 (21.6) |
TTF-1, thyroid transcription factor-1; PS, performance status; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; PD-L1, programmed death ligand-1.